These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

890 related articles for article (PubMed ID: 18094720)

  • 1. Novel antifungal agents as salvage therapy for invasive aspergillosis in patients with hematologic malignancies: posaconazole compared with high-dose lipid formulations of amphotericin B alone or in combination with caspofungin.
    Raad II; Hanna HA; Boktour M; Jiang Y; Torres HA; Afif C; Kontoyiannis DP; Hachem RY
    Leukemia; 2008 Mar; 22(3):496-503. PubMed ID: 18094720
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amphotericin B lipid complex versus liposomal amphotericin B monotherapy for invasive aspergillosis in patients with hematologic malignancy.
    Hachem RY; Boktour MR; Hanna HA; Husni RN; Torres HA; Afif C; Kontoyiannis DP; Raad II
    Cancer; 2008 Mar; 112(6):1282-7. PubMed ID: 18224662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low-dose amphotericin B lipid complex vs. conventional amphotericin B for empirical antifungal therapy of neutropenic fever in patients with hematologic malignancies--a randomized, controlled trial.
    Subirà M; Martino R; Gómez L; Martí JM; Estany C; Sierra J
    Eur J Haematol; 2004 May; 72(5):342-7. PubMed ID: 15059069
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Triple antifungal therapy for the treatment of invasive aspergillosis in a neutropenic pediatric patient.
    Sims-McCallum RP
    Am J Health Syst Pharm; 2003 Nov; 60(22):2352-6. PubMed ID: 14652986
    [No Abstract]   [Full Text] [Related]  

  • 5. Treatment of invasive fungal infections in high risk hematological patients. The outcome with liposomal amphotericin B is not negatively affected by prior administration of mold-active azoles.
    De la Serna J; Jarque I; López-Jiménez J; Fernández-Navarro JM; Gómez V; Jurado M; Pascual A; Serrano J; Romero M; Vallejo C
    Rev Esp Quimioter; 2013 Mar; 26(1):64-9. PubMed ID: 23546466
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of liposomal amphotericin B versus an amphotericin B lipid complex on liver histopathology in patients with hematologic malignancies and invasive fungal infections: a retrospective, nonrandomized autopsy study.
    Chamilos G; Luna M; Lewis RE; Chemaly R; Raad II; Kontoyiannis DP
    Clin Ther; 2007 Sep; 29(9):1980-6. PubMed ID: 18035197
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical experience of the use of voriconazole, caspofungin or the combination in primary and salvage therapy of invasive aspergillosis in haematological malignancies.
    Raad II; Zakhem AE; Helou GE; Jiang Y; Kontoyiannis DP; Hachem R
    Int J Antimicrob Agents; 2015 Mar; 45(3):283-8. PubMed ID: 25455847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of caspofungin as salvage therapy for invasive aspergillosis compared to standard therapy in a historical cohort.
    Hiemenz JW; Raad II; Maertens JA; Hachem RY; Saah AJ; Sable CA; Chodakewitz JA; Severino ME; Saddier P; Berman RS; Ryan DM; Dinubile MJ; Patterson TF; Denning DW; Walsh TJ
    Eur J Clin Microbiol Infect Dis; 2010 Nov; 29(11):1387-94. PubMed ID: 20703506
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Strategy of following voriconazole versus amphotericin B therapy with other licensed antifungal therapy for primary treatment of invasive aspergillosis: impact of other therapies on outcome.
    Patterson TF; Boucher HW; Herbrecht R; Denning DW; Lortholary O; Ribaud P; Rubin RH; Wingard JR; DePauw B; Schlamm HT; Troke P; Bennett JE; ;
    Clin Infect Dis; 2005 Nov; 41(10):1448-52. PubMed ID: 16231256
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination antifungal therapy for invasive aspergillosis.
    Marr KA; Boeckh M; Carter RA; Kim HW; Corey L
    Clin Infect Dis; 2004 Sep; 39(6):797-802. PubMed ID: 15472810
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A rescue therapy with a combination of caspofungin and liposomal amphotericin B or voriconazole in children with haematological malignancy and refractory invasive fungal infections.
    Yilmaz D; Balkan C; Ay Y; Akin M; Karapinar B; Kavakli K
    Mycoses; 2011 May; 54(3):234-42. PubMed ID: 19906090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does combination of lipid formulation of amphotericin B and echinocandins improve outcome of invasive aspergillosis in hematological malignancy patients?
    Mihu CN; Kassis C; Ramos ER; Jiang Y; Hachem RY; Raad II
    Cancer; 2010 Nov; 116(22):5290-6. PubMed ID: 20665889
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Cerebral aspergillosis in an HIV-infected patient: unsuccessful outcome despite combined antifungal therapy. ].
    Gasch O; Fernández N; Ayats J; Santin M
    Enferm Infecc Microbiol Clin; 2009 Mar; 27(3):193-4. PubMed ID: 19306722
    [No Abstract]   [Full Text] [Related]  

  • 14. Efficacy of Abelcet and caspofungin, alone or in combination, against CNS aspergillosis in a murine model.
    Imai J; Singh G; Fernandez B; Clemons KV; Stevens DA
    J Antimicrob Chemother; 2005 Jul; 56(1):166-71. PubMed ID: 15917284
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative efficacies of conventional amphotericin b, liposomal amphotericin B (AmBisome), caspofungin, micafungin, and voriconazole alone and in combination against experimental murine central nervous system aspergillosis.
    Clemons KV; Espiritu M; Parmar R; Stevens DA
    Antimicrob Agents Chemother; 2005 Dec; 49(12):4867-75. PubMed ID: 16304147
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High rate of breakthrough invasive aspergillosis among patients receiving caspofungin for persistent fever and neutropenia.
    Lafaurie M; Lapalu J; Raffoux E; Breton B; Lacroix C; Socié G; Porcher R; Ribaud P; Touratier S; Molina JM
    Clin Microbiol Infect; 2010 Aug; 16(8):1191-6. PubMed ID: 19735276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of Abelcet alone, or in combination therapy, against experimental central nervous system aspergillosis.
    Clemons KV; Parmar R; Martinez M; Stevens DA
    J Antimicrob Chemother; 2006 Aug; 58(2):466-9. PubMed ID: 16760192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Economic evaluation of targeted treatments of invasive aspergillosis in adult haematopoietic stem cell transplant recipients in the Netherlands: a modelling approach.
    Ament AJ; Hübben MW; Verweij PE; de Groot R; Warris A; Donnelly JP; van 't Wout J; Severens JL
    J Antimicrob Chemother; 2007 Aug; 60(2):385-93. PubMed ID: 17561501
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Update on therapy of invasive mycoses in hematology and oncology].
    Maschmeyer G; Haas A; Böhme A
    Dtsch Med Wochenschr; 2005 Jun; 130(22):1381-4. PubMed ID: 15915381
    [No Abstract]   [Full Text] [Related]  

  • 20. Voriconazole treatment for subacute invasive and chronic pulmonary aspergillosis.
    Sambatakou H; Dupont B; Lode H; Denning DW
    Am J Med; 2006 Jun; 119(6):527.e17-24. PubMed ID: 16750972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 45.